AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03295318 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted study formulation NmCV-5
Description: Adjuvanted formulation of polyvalent conjugate meningococcal vaccine against serogroups A,C,Y,W\&X (NmCV-5) is available as lyophilised powder of polysacchride antigens A\&X conjugated to tetanus toxoid and C,Y\&W conjugated to CRM protein. The diluent contains Alum as adjuvant with Normal Saline. Each antigen content is 5 micrograms per 0.5 mL dose of vaccine
Study NCT03295318 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menactra
Description: Menactra is available as ready to used solution containing polysacchride antigens A,C,Y\&WX conjugated to diphtheria toxoid. Each antigen content is 4 micrograms per 0.5 mL dose of vaccine.
Study NCT00266825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHA
Description: 600 mg DHA
Study NCT00266825 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Placebo capsule
Study NCT01514526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dovitinib
Description: Dovitinib (TKI-258), gelatin capsule of 100mg, developed and supplied by Novartis Inc. The study regimen consists of the administration of 500 mg / day (5 x 100mg) once daily, taken orally with a large amount of water, preferably one hour prior to a meal or at least two hours following a meal. This dose will be taken once daily according to 5 days on/2 days off schedule.~The patient will continue on treatment until disease progression,unacceptable toxicity, death or premature withdrawal.
Study NCT01573936 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy, occupational therapy, psycotherapy, medical consultations
Description: The mean duration of the RP was 7.47 ± 4.45 months, but it was not standardized because this factor was not one of the parameters of interest for this study
Study NCT03154489 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: acenocoumarol
Description: medication review with follow-up in acenocoumarol treatment
Study NCT03154489 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: control
Description: group
Study NCT01839006 — intervention group
Intervention type: PROCEDURE
Intervention: dismembered pyeloplasty
Description: Using a flank approach, as the patient was placed in the lateral decubitus position, and an anterior subcostal incision was made. The narrow segment of UPJ was identified and resected, and then the proximal edge of the ureter was spatulated to allow a wide anastomosis between the ureter and the most dependent part of the renal pelvis. The extent of renal pelvis reduction was decided by the surgeon.
Study NCT02489032 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SBIRT Training & Support Tool
Description: Program to train EAP/behavioral health practitioners in conducting alcohol SBIRT
Study NCT02489032 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Waitlist Control
Description: 3-month wait-list and then provided access to the SBIRT training program
Study NCT03559101 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Distilled water
Description: Commercially available beverage~Subjects collect all morning urine and drink 500 milliliters of water. Baseline vital measurements (heart rate, blood pressure, oral temperature) and body weight collected Baseline blood samples and urine collected Beverage pretreatment consumed (1 liter over 30 minutes) Body weight measured and blood and urine collected at 5 minutes, 10 minutes, 15 minutes, and then every 30 minutes for 4 hours post beverage consumption
Study NCT03559101 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Food 1
Description: Commercially available beverage~Subjects collect all morning urine and drink 500 milliliters of water. Baseline vital measurements (heart rate, blood pressure, oral temperature) and body weight collected Baseline blood samples and urine collected Beverage pretreatment consumed (1 liter over 30 minutes) Body weight measured and blood and urine collected at 5 minutes, 10 minutes, 15 minutes, and then every 30 minutes for 4 hours post beverage consumption
Study NCT03559101 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Food 2
Description: Commercially available beverage~Subjects collect all morning urine and drink 500 milliliters of water. Baseline vital measurements (heart rate, blood pressure, oral temperature) and body weight collected Baseline blood samples and urine collected Beverage pretreatment consumed (1 liter over 30 minutes) Body weight measured and blood and urine collected at 5 minutes, 10 minutes, 15 minutes, and then every 30 minutes for 4 hours post beverage consumption
Study NCT03559101 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pedialyte
Description: Commercially available beverage~Subjects collect all morning urine and drink 500 milliliters of water. Baseline vital measurements (heart rate, blood pressure, oral temperature) and body weight collected Baseline blood samples and urine collected Beverage pretreatment consumed (1 liter over 30 minutes) Body weight measured and blood and urine collected at 5 minutes, 10 minutes, 15 minutes, and then every 30 minutes for 4 hours post beverage consumption
Study NCT03559101 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gatorade
Description: Commercially available beverage~Subjects collect all morning urine and drink 500 milliliters of water. Baseline vital measurements (heart rate, blood pressure, oral temperature) and body weight collected Baseline blood samples and urine collected Beverage pretreatment consumed (1 liter over 30 minutes) Body weight measured and blood and urine collected at 5 minutes, 10 minutes, 15 minutes, and then every 30 minutes for 4 hours post beverage consumption
Study NCT03671174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 10mg once daily orally
Study NCT03671174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: 100mg to 200mg twice daily orally
Study NCT03671174 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 50mg once daily orally
Study NCT03671174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 50mg once daily orally
Study NCT03671174 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: low molecular weight heparin
Description: Enoxaparin 40mg once daily subcutaneous or dalteparin 5000IU once daily subcutaneous or nadroparin calcium 4100U once daily subcutaneous
Study NCT03671174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low molecular weight heparin
Description: Enoxaparin 40mg once daily subcutaneous or dalteparin 5000IU once daily subcutaneous or nadroparin calcium 4100U once daily subcutaneous
Study NCT04547725 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CRS followed by IP and systemic chemotherapies
Description: Complete cytoreductive surgery (CRS) + normothermic intraperitoneal chemotherapy (N-IPEC) + systemic chemotherapy
Study NCT03600584 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified one-layer duct-to-mucosa Pancreaticojejunostomy
Description: After the completion of the preparation of the remnant pancreas for reconstruction was performed. Modified one-layer duct-to-mucosa Pancreaticojejunostomy was performed.
Study NCT03600584 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Invagination pancreaticojejunostomy
Description: After the completion of the preparation of the remnant pancreas for reconstruction was performed. Invagination Pancreaticojejunostomy was performed.
Study NCT03887338 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Transnasal Fiberoptic Laryngoscopy
Description: Use of Transnasal Fiberoptic Laryngoscopy during NIV titration to optimalize the NIV settings to laryngeal responses during the NIV treatment.
Study NCT03754179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Upfront treatment with dabrafenib, trametinib and hydroxychloroquine in phase 1 and Arm A phase 2.~Upfront treatment with dabrafenib and trametinib in Arm B phase 2 with add-on of hydroxychloroquine at progression of disease
Study NCT03754179 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabrafenib
Description: Upfront treatment with dabrafenib, trametinib and hydroxychloroquine in phase 1 and Arm A phase 2.~Upfront treatment with dabrafenib and trametinib in Arm B phase 2 with add-on of hydroxychloroquine at progression of disease
Study NCT03754179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Upfront treatment with dabrafenib, trametinib and hydroxychloroquine in phase 1 and Arm A phase 2.~Upfront treatment with dabrafenib and trametinib in Arm B phase 2 with add-on of hydroxychloroquine at progression of disease
Study NCT03754179 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trametinib
Description: Upfront treatment with dabrafenib, trametinib and hydroxychloroquine in phase 1 and Arm A phase 2.~Upfront treatment with dabrafenib and trametinib in Arm B phase 2 with add-on of hydroxychloroquine at progression of disease
Study NCT03754179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Upfront treatment with dabrafenib, trametinib and hydroxychloroquine in phase 1 and Arm A phase 2. Add-on at progression of disease in Arm B phase 2
Study NCT03754179 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Upfront treatment with dabrafenib, trametinib and hydroxychloroquine in phase 1 and Arm A phase 2. Add-on at progression of disease in Arm B phase 2
Study NCT01257776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Autologous adipose derived mesenchymal stem cells
Description: Intra-arterial administration through a selective cannulation of target common femoral artery
Study NCT01557387 — intervention group
Intervention type: OTHER
Intervention: Endoscopic techniques
Description: All patients will undergo non-invasive endoscopic techniques considered standard of care in surveillance for dysplasia
Study NCT04636372 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intense pulsed light therapy
Description: Patients with xerophthalmia were treated with intense pulsed light of meibomian gland.
Study NCT04636372 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hot compress massage
Description: Patients with xerophthalmia were treated with hot compress massage of meibomian gland.
Study NCT01127646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: 25-80 milligrams (mg) administered orally, once daily.
Study NCT01127646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Osmotic-release oral system methylphenidate
Description: 18-54 mg administered orally, once daily.
Study NCT01127646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally, once daily for random nonconsecutive 6 days during 4-week treatment period.
Study NCT01127646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Administered orally, once daily for random nonconsecutive 6 days during 4-week treatment period.
Study NCT02598648 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: FXR
Description: FXR could elevate the transcription of RIPK3, a key protein in necroptosis, and play important role in bile aicd induced alveolar epithelial cell(AEC) necroptosis. FXR were measured in neonate with ALI、ARDS and control
Study NCT02598648 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: RIPK3
Description: FXR(farnesoid-X-receptor) could elevate the transcription of RIPK3, a key protein in necroptosis, and play important role in bile aicd induced alveolar epithelial cell(AEC) necroptosis. RIPK3 were measured in neonate with ALI、ARDS and control.
Study NCT02112240 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraoperative Mobile Gamma Camera imaging
Description: Intraoperative images will be taken with a unique mobile gamma camera to identify sentinel lymph nodes in the rectum.
Study NCT02112240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endoscopic injection of 99mTc-sulfur colloid
Description: Radiotracer injection around the rectal tumor for pre- and intra-operative imaging.
Study NCT02112240 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endoscopic injections of Spot
Description: Dye injection for tattooing rectal tumor prior to surgical resection.
Study NCT02112240 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preoperative flexible sigmoidoscopy
Description: Flexible sigmoidoscopy prior to surgery to facilitate endoscopic injections of radiotracer and dye.
Study NCT02112240 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SPECT/CT
Description: Preoperative imaging to identify lymph nodes in rectum.
Study NCT02625545 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UroLift System procedure
Description: Minimally invasive procedure for treatment of lower urinary tract symptoms (LUTS) due to BPH
Study NCT03085446 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PDM nutritional intervention
Description: personalized, diet-induced alterations in microbiota (PDM) for six months. (1) A 14-day running-in, no-treatment baseline assessment of all outcomes (T0); (2) A 6-month intervention period, with repeated assessments of all outcomes during the last two weeks of months 3 (T1) and 6 (T2). (3) A 12 month follow up (T3).
Study NCT03085446 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: General information on nutrition and health
Description: General information on nutrition and health for six months: (1) A 14-day running-in, no-treatment baseline assessment of all outcomes (T0); (2) A 6-month intervention period, with repeated assessments of all outcomes during the last two weeks of months 3 (T1) and 6 (T2). (3) A 12 month follow up (T3),
Study NCT05207215 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Base Exercises
Description: The study developed 3 approaches that innovate beyond the existing delivery modes of the SAFE programme, by developing means for providing an intervention that is functionally equivalent to the SAFE programme but can be implemented in a patient's home. These home approaches include: (a) video conferencing; (b) gamification; and (3) self-guided home exercise programme. The investigators' task is to focus on developing these 3 modes and evaluating each in a pilot context for participants upon discharge from the hospital.
Study NCT05207215 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Home Base Exercises
Description: The study developed 3 approaches that innovate beyond the existing delivery modes of the SAFE programme, by developing means for providing an intervention that is functionally equivalent to the SAFE programme but can be implemented in a patient's home. These home approaches include: (a) video conferencing; (b) gamification; and (3) self-guided home exercise programme. The investigators' task is to focus on developing these 3 modes and evaluating each in a pilot context for participants upon discharge from the hospital.
Study NCT02688400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diacerein
Study NCT01546961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: Chloroquine phosphate GPO® (Government Pharmaceutical Organization, Thailand) 250 mg (equivalent to chloroquine base 150 mg).~Dosing will be at 0, 24, 48 hrs with 10 mg/kg on day 0 and day 1, and 5 mg/kg on day 2.
Study NCT02688400 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Study NCT02688400 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT02688400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT03045432 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: oral-teaching
Description: The nurses will teach patients how to position their affected arm properly, how to transfer safely with the help from the caregivers, how to execute appropriate passive range of motion exercises regularly, and be taught to be aware of not doing insecure pulley exercises nor carrying stuffs which are too heavy on the admission date of hospitalization.
Study NCT03045432 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral-teaching
Description: The nurses will teach patients how to position their affected arm properly, how to transfer safely with the help from the caregivers, how to execute appropriate passive range of motion exercises regularly, and be taught to be aware of not doing insecure pulley exercises nor carrying stuffs which are too heavy on the admission date of hospitalization.
Study NCT03045432 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: regular rehabilitation program
Description: Regular occupational therapy program and regular physical therapy program in the rehabilitation department of the hospital.
Study NCT03045432 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: regular rehabilitation program
Description: Regular occupational therapy program and regular physical therapy program in the rehabilitation department of the hospital.
Study NCT00917163 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Supralimus(R) Sirolimus-Eluting Coronary Stent System
Description: Drug eluting stent implantation in the treatment of coronary artery disease.
Study NCT00917163 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xience V™ Everolimus Eluting Coronary Stent
Description: Drug eluting stent implantation in the treatment of coronary artery disease
Study NCT00002558 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00002558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study NCT00002558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study NCT00002558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Study NCT00002558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study NCT00002558 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study NCT03605433 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban
Description: Rivaroxaban 2.5 mg or Rivaroxaban 20 mg or no oral anticoagulation
Study NCT03605433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Rivaroxaban 2.5 mg or Rivaroxaban 20 mg or no oral anticoagulation
Study NCT05080062 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Requirements and functional Schedule
Description: An interview with the employee and the employer where the occupational worker is leading the interview and a pain rehabilitation-program
Study NCT05080062 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Description: a pain rehabilitation-program
Study NCT03577860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 4 mL
Description: The interscalene brachial plexus block is performed with 4ml of bupivacaine-epinephrine 0,5%- 1:200,000
Study NCT03577860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 15 mL
Description: The interscalene brachial plexus block is performed with 15ml of bupivacaine-epinephrine 0,5%- 1:200,000
Study NCT00548730 — intervention group
Intervention type: PROCEDURE
Intervention: Bronchoscopy
Description: The endoscopic examination of the bronchial tree will be performed using a commercially available flexible fluorescence bronchoscope and the flexible white light video-bronchoscope. Biopsies are taken of a normal region and all abnormal regions.
Study NCT02344446 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skilled Therapy
Description: Active physical therapy treatment
Study NCT01359670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Escalating dose (0.25 mg/kg, 0.5 mg/kg, 1.0 mg/kg; once daily) over 2 weeks
Study NCT01359670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Escalating dose (0.25 mg/kg, 0.5 mg/kg, 1.0 mg/kg; four times daily) over 2 weeks
Study NCT00760539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004%/Timolol 0.5% BAC-free ophthalmic solution
Study NCT00760539 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Travoprost 0.004%/Timolol 0.5% ophthalmic solution
Study NCT04218448 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypnorelaxation
Description: Hypno-relaxation is induced by following VAKOG: external sensory identification, fixation of attention, bodily sensation, breathing, sensory perceptions, closing of the eyes.~The work phase follows induction and allows deepening of the hypnotic trance. It corresponds to a metaphorical narrative associated with post-hypnotic suggestions and is fueled by the construction of adapted suggestions and metaphors, adapted to each patient. The investigator who remains present throughout the duration of the examination, maintains a hypnotic, empathetic, attentive attitude, and makes it possible to recover this material. Using the elements previously supplied by the patient, the investigator tells a story which allows the patient to focus his attention on something other than the performance of the somatosensory evoked potentials examination. The investigator, thanks to hypnosis, allows the development
Study NCT03262610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setmelanotide
Description: daily subcutaneous injection
Study NCT04111250 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maxillary sinus augmentation
Description: Raise the sinus membrane to graft bone substitute to augment the sinus cavity allowing implants placement.